Corresponding author

Conti, C. Lasagni, L. Bigi, G. Pellacani

Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena 41124, Italy.

Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.

  • Case 1: 62-year-old man, affected by hypertension, diabetes, chronic renal failure and overweight (BMI: 29), receiving guselkumab since November 2019, who developed a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on February 23th, with admission to an intensive care unit for two weeks. After one month of hospitalization, he was discharged with almost complete resolution of respiratory symptoms; despite discontinuation of guselkumab, psoriasis remained in complete remission.
  • Case 2: 66-year-old man, health volunteer, affected by hypertension, dyslipidemia and previous myocardial infarction, receiving ustekinumab since 2010; on March 15th, seven days after the last administration of the drug, he presented asthenia, anosmia and ageusia. On March 18th, he was tested positive for COVID-19 and he didn’t receive any pharmacological treatment; after a complete remission of symptoms, on April 15th he was tested negative, with maintenance of the remission of psoriasis.
  • Case 3: 67-year-old woman, affected by hypertension and metabolic syndrome, receiving adalimumab since September 2019, at the end of February had several contacts with three of her family members suffering from a mild SARS-CoV-2 and she was therefore subjected to quarantine for fifteen days, without developing any symptoms of the disease and without stopping psoriasis therapy.
  • Case 4: 66-year-old man, affected by hypertension, diabetes, metabolic syndrome and obesity (BMI: 32), receiving secukinumab since October 2018, had a continuous contact with his wife affected by al mild SARS-CoV-2 infection since March 17th; he was therefore quarantined for fifteen days, without developing any symptoms of the disease and without stopping psoriasis therapy. In the last two cases, the biologic therapy was interrupted only during the quarantine period, without worsening of psoriasis and no test has be done for COVID-19.

In SARS-CoV-2 infection the immune response plays an important role in the development of an excessive inflammatory response, which can evolve towards an acute respiratory distress syndrome (ARDS), potentially lethal for the patient (3). Some key cytokines in the pathogenesis of psoriasis, such as Tumor Necrosis Factor Alpha (TNF-) and Interleukin 17 (IL17) are increased in inflammatory response to coronavirus and viral pneumonia, while IL-23 does not seem to be essential for an effective immune response (4). The increase in inflammatory cytokines is associated to a worsening of clinical conditions of the patients affected by SARS-CoV-2 (3,5). Based on these observations, it has been hypothesized that anti-TNF- or anti-IL17 drugs could play a potential role to improve COVID-19’s “cytokine storm” and ARDS (6). For this reason, the use of ixekizumab and adalimumab associated to antiviral drugs are currently studied in China in the treatment for Covid-19 (7,8). Despite the presence of risk factors for a worse prognosis (hypertension, diabetes, obesity, male gender), only one patient presented a severe form of SARS-CoV-2, while another one a mild form. Despite a prolonged contact with subjects with COVID-19 infection, the other two cases did not show any symptoms. This could explain the positive course of COVID-19 infection in our four cases, where ongoing treatment with biological drugs could play a protective role against the onset and the evolution of the infection. Further studies are needed to investigate this hypothesis.

References

  1. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020 Mar 18; doi.org/10.1016/j.jaad.2020.03.031
  2. Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16468.
  3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
  4. Shi X, Zhou W, Huang H, et al. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Crit Care 2013;17: R301.
  5. Chen C, Zhang X, Ju Z, He W. Research progress on the mechanism of cytokine storm induced by new coronavirus pneumonia and related immunotherapy [J/OL]. Chinese Journal of Burns, 2020, 36 (2020-03-02). doi: 10.3760 / cma.j.cn501120-20200224-00088.
  6. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020;395: e35-e36.
  7. A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) http://www.chictr.org.cn/showprojen.aspx?proj=50251 (last accessed 19 April 2020).
  8. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) http://www.chictr.org.cn/showprojen.aspx?proj=49889 (last accessed 19 April 2020).